Stock Movers Merck Ends Talks to Buy Revolution Medicines; USA Rare Earth Surges; Nvidia Invests an Additional $2 Billion in CoreWeave
Jan 26, 2026
Deal talks between a major pharma and a biotech collapse over price disagreements. A domestic rare-earth firm secures a massive funding letter and fresh private capital to boost production. A leading AI chipmaker pours another $2 billion into an AI cloud provider to expand computing capacity and roll out new hardware and services.
AI Snips
Chapters
Transcript
Episode notes
Merck-Revolution Talks Collapse
- Merck halted talks to buy Revolution Medicines after failing to agree on price for a potential ~$30 billion deal.
- Alexis Christophorus notes talks could resume or another suitor may emerge, highlighting persistent strategic interest.
Government Funding For Rare Earths
- USA Rare Earth struck a non-binding LOI with the Commerce Department for $1.6 billion and will give a stake and warrants to the government.
- Alexis Christophorus highlights this is part of a broader U.S. push to reduce reliance on China for critical rare-earths.
Private Capital Joins Rare-Earth Push
- USA Rare Earth also announced a separate $1.5 billion private investment to accelerate domestic heavy rare-earth production.
- Alexis Christophorus calls the company a concept stock with little near-term revenue but big market cap potential.